A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 1, 2011, Pages 157-164

  Kanai, Masashi ^a   Yoshimura, Kenichi ^a   Asada, Masanori ^b   Imaizumi, Atsushi ^c   Suzuki, Chihiro ^a   Matsumoto, Shigemi ^a   Nishimura, Takafumi ^a   Mori, Yukiko ^a   Masui, Toshihiko ^a   Kawaguchi, Yoshiya ^a   Yanagihara, Kazuhiro ^a   Yazumi, Shujiro ^b   Chiba, Tsutomu ^a   Guha, Sushovan ^d   Aggarwal, Bharat B ^d  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b Kitano Hospital   (Japan)

^c Theravalues Corporation   (Japan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Curcumin; Gemcitabine; Pancreatic cancer

Indexed keywords

CURCUMIN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EDEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL OBSTRUCTION; HAND FOOT SYNDROME; HUMAN; MALE; MONOTHERAPY; NAUSEA; PANCREAS CANCER; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STOMATITIS; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CURCUMIN; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 79959612772     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1470-2     Document Type: Article

References (29)

1. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69:195-206 (Pubitemid 43048906)
2. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, Sarkar FH (2010) Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70:3606-3617
3. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C, Chollet P (2010) Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9:8-14
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
5. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895-2900
6. Corson TW, Crews CM (2007) Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130:769-774 (Pubitemid 47332575)
7. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491-4499
8. Du B, Jiang L, Xia Q, Zhong L (2006) Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 52:23-28 (Pubitemid 43004433)
9. Eckel F, Schneider G, Schmid RM (2006) Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs 15:1395-1410 (Pubitemid 44615288)
10. Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R (2009) The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res 15:5917-5922
11. Kanai M, Konda Y, Nakajima T, Izumi Y, Takeuchi T, Chiba T (2001) TGF-alpha inhibits apoptosis of murine gastric pit cells through an NF-kappaB-dependent pathway. Gastroenterology 121:56-67 (Pubitemid 32591515)
12. Koo JY, Kim HJ, Jung KO, Park KY (2004) Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J Med Food 7:117-121 (Pubitemid 38891062)
13. Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB (1998) Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 55:775-783 (Pubitemid 28319640)
14. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853-3861 (Pubitemid 46762173)
15. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K (2004) Pancreatic cancer registry in Japan: 20 years of experience. Pancreas 28:219-230 (Pubitemid 38437313)
16. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB (2002) Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21:8852-8861 (Pubitemid 36132405)
17. Oettle HPU, Stieler J et al (2005) Oxaliplatin/follnic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in secondary-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 23:315s
18. Pisters PW, Wolff RA, Crane CH, Evans DB (2005) Combined-modality treatment for operable pancreatic adenocarcinoma. Oncology 19:393-404
19. Saif MW (2008) Is there a role for herbal medicine in the treatment of pancreatic cancer? Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30-June 3, 2008. JOP 9:403-407
20. Sen S, Sharma H, Singh N (2005) Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun 331:1245-1252 (Pubitemid 40692490)
21. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847-6854 (Pubitemid 39383033)
22. Sharma S, Kulkarni SK, Agrewala JN, Chopra K (2006) Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol 536:256-261
23. Strimpakos AS, Sharma RA (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10:511-545
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
25. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181 (Pubitemid 36962641)
26. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17:1411-1417
27. Xu Y, Ku BS, Yao HY, Lin YH, Ma X, Zhang YH, Li XJ (2005) Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 82:200-206 (Pubitemid 41423504)
28. Xu Y, Ku BS, Yao HY, Lin YH, Ma X, Zhang YH, Li XJ (2005) The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 518:40-46 (Pubitemid 40968146)
29. Yamauchi J, Kanai M, Matsumoto S, Nishimura T, Yazumi S, Kami K, Kawaguchi Y, Yasuda H, Kitano T, Misawa A, Ishiguro H, Yoshikawa K, Yanagihara K, Fukushima M, Doi R, Chiba T (2008) Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer. Pancreas 36:327-328 (Pubitemid 351440944)